ArticleThe European journal of health economics : HEPAC : health economics in prevention and care2024

Cost-effectiveness of encorafenib with binimetinib in unresectable or metastatic BRAF-mutant melanoma.

Jean-Baptiste Trouiller et al.PubMed ↗Publisher ↗

No numbers read from the abstract.